Entering text into the input field will update the search result below

European advisory group backs Roche's entrectinib

May 29, 2020 7:44 AM ETRoche Holding AG (RHHBY) StockRHHBYBy: Douglas W. House, SA News Editor
  • The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Roche's (OTCQX:RHHBY) Rozlytrek (entrectinib) for the treatment of patients with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion or patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG